- Abstract
- Core Tip
- Article Highlights
- Full Article (PDF)
- Full Article with Cover (PDF)
- Full Article (XML)
- Full Article (HTML)
- Audio
- PubMed Central
- PubMed
- CrossRef
- Google Scholar
- Similar Articles (289)
- Timeline of Article Publication (1)
- Authors Evaluation (3)
- Article Quality Tracking (0)
- Reference Citation Analysis (1)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4593)
All Articles published online
|
Publishing Process of This Article
|
Mar 21, 2024 (publication date) through Jun 14, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Csontos A, Fazekas A, Szakó L, Farkas N, Papp C, Ferenczi S, Bellyei S, Hegyi P, Papp A. Effects of neoadjuvant chemotherapy vs chemoradiotherapy in the treatment of esophageal adenocarcinoma: A systematic review and meta-analysis. World J Gastroenterol 2024; 30(11): 1621-1635 [PMID: 38617451 DOI: 10.3748/wjg.v30.i11.1621] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v30/i11/1621.htm |
| Number | Citing Articles |
| 1 |
Xiaodan Shao, Na Wang, Ke Tang, Kunning Wang, Zhangyan Tan, Jiangxiu Xie, Zhiwei Shen, Yuting Jiang, Yan Zhang. Network analysis used to investigate the symptoms of cancer patients during chemotherapy: a scoping review. Discover Oncology 2025; 16(1) doi: 10.1007/s12672-025-02837-0
|
| 2 |
Xihao Xie, Hai Zhang, Haiquan He, Bomeng Wu, Ying Chen, Wanli Lin, Qingyi Feng, Qunqing Chen. Postoperative adjuvant immunotherapy for pathological stage II–IVa esophageal squamous cell carcinoma after radical surgery does not improve disease-free recurrence rates. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1517001
|